Thierry Passeron

Nice, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 394 publications

Upadacitinib for Severe Alopecia Areata in Adults and Adolescents: Two Phase 3 UP-AA Randomized Clinical Trials.

Upadacitinib for Severe Alopecia Areata in Adults and Adolescents: Two Phase 3 UP-AA Randomized Clinical Trials.

Journal: JAMA dermatology
Published: August 12, 2026

Efficacy of ruxolitinib cream in a patient with lupus miliaris disseminatus faciei.

Efficacy of ruxolitinib cream in a patient with lupus miliaris disseminatus faciei.

Journal: JAAD case reports
Published: May 22, 2026

Vitiligo and skin cancer risk across racial/ethnic groups: A retrospective propensity score-matched study on 123,179 patients.

Vitiligo and skin cancer risk across racial/ethnic groups: A retrospective propensity score-matched study on 123,179 patients.

Journal: European journal of cancer (Oxford, England : 1990)
Published: May 20, 2026

Combined Oral Ivermectin and 5% Permethrin Cream to Treat Severe Scabies.

Combined Oral Ivermectin and 5% Permethrin Cream to Treat Severe Scabies.

Journal: The New England journal of medicine
Published: May 06, 2026

Real-World Treatment Patterns, Healthcare Resource Utilisation, and Costs in Biologic-Naïve Patients with Moderate-to-Severe Psoriasis Treated with Biologics in France.

Real-World Treatment Patterns, Healthcare Resource Utilisation, and Costs in Biologic-Naïve Patients with Moderate-to-Severe Psoriasis Treated with Biologics in France.

Journal: Dermatology and therapy
Published: April 10, 2026

Definition of Severity and Relapse for Vitiligo: An International Consensus Statement.

Definition of Severity and Relapse for Vitiligo: An International Consensus Statement.

Journal: JAMA dermatology
Published: March 25, 2026

Post Hoc Subgroup and Body Region Analyses of VASI Outcomes Among Patients with Vitiligo in a Phase 2 Povorcitinib Trial.

Post Hoc Subgroup and Body Region Analyses of VASI Outcomes Among Patients with Vitiligo in a Phase 2 Povorcitinib Trial.

Journal: Advances in therapy
Published: March 11, 2026

Biological Photoprotection: A Review of its Mechanisms, Evidence, and Clinical Implications.

Biological Photoprotection: A Review of its Mechanisms, Evidence, and Clinical Implications.

Journal: Dermatology and therapy
Published: March 10, 2026

Ten-year longitudinal assessment of entheseal ultrasound in psoriasis: limited discriminatory capacity for psoriatic arthritis.

Ten-year longitudinal assessment of entheseal ultrasound in psoriasis: limited discriminatory capacity for psoriatic arthritis.

Journal: Rheumatology advances in practice
Published: March 04, 2026

The impact of the six pillars of lifestyle medicine on the biology of skin aging.

The impact of the six pillars of lifestyle medicine on the biology of skin aging.

Journal: Frontiers in aging
Published: March 03, 2026

International modified Delphi consensus statement on visible light photoprotection: Effects, measurement, and recommendations.

International modified Delphi consensus statement on visible light photoprotection: Effects, measurement, and recommendations.

Journal: The Journal of investigative dermatology
Published: February 28, 2026

Efficacy and safety of upadacitinib in adults and adolescents for treatment of non-segmental vitiligo (Viti-Up): results of two phase 3 randomised controlled studies.

Efficacy and safety of upadacitinib in adults and adolescents for treatment of non-segmental vitiligo (Viti-Up): results of two phase 3 randomised controlled studies.

Journal: Lancet (London, England)
Published: February 27, 2026
Showing 1-12 of 394

Last Updated: 09/26/2026